156 related articles for article (PubMed ID: 32228895)
1. Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells.
Cristofolini T; Dalmina M; Sierra JA; Silva AH; Pasa AA; Pittella F; Creczynski-Pasa TB
Mater Sci Eng C Mater Biol Appl; 2020 Apr; 109():110555. PubMed ID: 32228895
[TBL] [Abstract][Full Text] [Related]
2. Magnetically responsive hybrid nanoparticles for in vitro siRNA delivery to breast cancer cells.
Dalmina M; Pittella F; Sierra JA; Souza GRR; Silva AH; Pasa AA; Creczynski-Pasa TB
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1182-1190. PubMed ID: 30889652
[TBL] [Abstract][Full Text] [Related]
3. Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.
Gu S; Ngamcherdtrakul W; Reda M; Hu Z; Gray JW; Yantasee W
PLoS One; 2018; 13(6):e0198141. PubMed ID: 29879129
[TBL] [Abstract][Full Text] [Related]
4. Her2/neu small interfering RNA delivered in culture by a streptavidin nanoparticle.
Liu X; Nakamura K; Cheng D; Peng C; Xiao N; Liu Y; Chen L; Rusckowski M; Hnatowich DJ
Curr Drug Deliv; 2012 Jul; 9(4):431-6. PubMed ID: 22520071
[TBL] [Abstract][Full Text] [Related]
5. Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency.
Bruniaux J; Allard-Vannier E; Aubrey N; Lakhrif Z; Ben Djemaa S; Eljack S; Marchais H; Hervé-Aubert K; Chourpa I; David S
Int J Pharm; 2019 Oct; 569():118572. PubMed ID: 31352052
[TBL] [Abstract][Full Text] [Related]
6. HER2 siRNA Facilitated Gene Silencing Coupled with Doxorubicin Delivery: A Dual Responsive Nanoplatform Abrogates Breast Cancer.
M G A; K S A; B S U; P L R; H P S; J S; Joseph MM; T T S
ACS Appl Mater Interfaces; 2024 May; 16(20):25710-25726. PubMed ID: 38739808
[TBL] [Abstract][Full Text] [Related]
7. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
8. Short interfering RNA delivered by a hybrid nanoparticle targeting VEGF: Biodistribution and anti-tumor effect.
Souza GRR; Dalmina M; Restrepo JAS; de Mello Junior LJ; Silva AH; Gualberto A; Gameiro J; Dittz D; Pasa AA; Pittella F; Creczynski-Pasa TB
Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129938. PubMed ID: 34062235
[TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo.
Wang X; Sun Q; Cui C; Li J; Wang Y
Drug Des Devel Ther; 2018; 12():2841-2855. PubMed ID: 30233146
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
11. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity.
Pittella F; Zhang M; Lee Y; Kim HJ; Tockary T; Osada K; Ishii T; Miyata K; Nishiyama N; Kataoka K
Biomaterials; 2011 Apr; 32(11):3106-14. PubMed ID: 21272932
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
[TBL] [Abstract][Full Text] [Related]
13. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference.
Tan WB; Jiang S; Zhang Y
Biomaterials; 2007 Mar; 28(8):1565-71. PubMed ID: 17161865
[TBL] [Abstract][Full Text] [Related]
14. Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells.
Li J; Xu W; Yuan X; Chen H; Song H; Wang B; Han J
Int J Nanomedicine; 2017; 12():6909-6921. PubMed ID: 29075110
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
16. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
17. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer.
Zhang L; Mu C; Zhang T; Wang Y; Wang Y; Fan L; Liu C; Chen H; Shen J; Wei K; Li H
ACS Appl Mater Interfaces; 2020 Jul; 12(29):32360-32371. PubMed ID: 32613835
[TBL] [Abstract][Full Text] [Related]
18. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H
Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334
[TBL] [Abstract][Full Text] [Related]
19. Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.
Ngamcherdtrakul W; Castro DJ; Gu S; Morry J; Reda M; Gray JW; Yantasee W
Cancer Treat Rev; 2016 Apr; 45():19-29. PubMed ID: 26930249
[TBL] [Abstract][Full Text] [Related]
20. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
